CN101550119B - 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 - Google Patents
芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 Download PDFInfo
- Publication number
- CN101550119B CN101550119B CN2009100266979A CN200910026697A CN101550119B CN 101550119 B CN101550119 B CN 101550119B CN 2009100266979 A CN2009100266979 A CN 2009100266979A CN 200910026697 A CN200910026697 A CN 200910026697A CN 101550119 B CN101550119 B CN 101550119B
- Authority
- CN
- China
- Prior art keywords
- preparation
- aryl
- xitix
- acid
- ascorbyl ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- -1 propanoic acid ascorbyl ester Chemical class 0.000 title claims abstract description 22
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 125000003118 aryl group Chemical group 0.000 title claims abstract description 12
- 235000019260 propionic acid Nutrition 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
- 230000000202 analgesic effect Effects 0.000 claims abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 4
- 208000006011 Stroke Diseases 0.000 claims abstract description 4
- 208000029028 brain injury Diseases 0.000 claims abstract description 4
- 208000003278 patent ductus arteriosus Diseases 0.000 claims abstract description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 3
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 3
- 230000036592 analgesia Effects 0.000 claims abstract description 3
- 206010003246 arthritis Diseases 0.000 claims abstract description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 13
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 10
- 239000003513 alkali Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 230000032050 esterification Effects 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000012429 reaction media Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 claims description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 2
- 108010084311 Novozyme 435 Proteins 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000002608 ionic liquid Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract description 22
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 abstract description 4
- 230000001754 anti-pyretic effect Effects 0.000 abstract description 3
- 229960000991 ketoprofen Drugs 0.000 abstract description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 abstract description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002221 antipyretic Substances 0.000 abstract description 2
- 229960002009 naproxen Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000003907 antipyretic analgesic agent Substances 0.000 abstract 1
- 230000006931 brain damage Effects 0.000 abstract 1
- 231100000874 brain damage Toxicity 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 11
- 238000004452 microanalysis Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- GCCOJNYCFNSJII-VWMHFEHESA-N [n'-[(4s)-4-amino-4-carboxybutyl]carbamimidoyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 GCCOJNYCFNSJII-VWMHFEHESA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960003428 dexibuprofen Drugs 0.000 description 2
- 229960002783 dexketoprofen Drugs 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- DJXLHSXYGKGZOW-QLIYLNMASA-N CC(C(OC[C@@H]([C@H](C(O)=C1O)OC1=O)O)=O)c1ccc(CC(CCC2)C2=O)cc1 Chemical compound CC(C(OC[C@@H]([C@H](C(O)=C1O)OC1=O)O)=O)c1ccc(CC(CCC2)C2=O)cc1 DJXLHSXYGKGZOW-QLIYLNMASA-N 0.000 description 1
- ZQTNXXZZAJDJNM-PZSREKOKSA-N CC(C)Cc1ccc([C@H](C)C(OC[C@@H]([C@H](C(O)=C2O)OC2=O)O)=O)cc1 Chemical compound CC(C)Cc1ccc([C@H](C)C(OC[C@@H]([C@H](C(O)=C2O)OC2=O)O)=O)cc1 ZQTNXXZZAJDJNM-PZSREKOKSA-N 0.000 description 1
- PQSKFLONTIJYBF-UHFFFAOYSA-N CC(C)c(cc1)cc(F)c1-c(cc1)ccc1O Chemical compound CC(C)c(cc1)cc(F)c1-c(cc1)ccc1O PQSKFLONTIJYBF-UHFFFAOYSA-N 0.000 description 1
- ZLHAKXLWCQVWFW-UHFFFAOYSA-N CC(C)c1cc(OC2=C(C3)C=CCN2)c3cc1 Chemical compound CC(C)c1cc(OC2=C(C3)C=CCN2)c3cc1 ZLHAKXLWCQVWFW-UHFFFAOYSA-N 0.000 description 1
- AVEKESWOQKDHBQ-ODLFYWEKSA-N CCC(c1cc(F)ccc11)=C(C)/C1=C/c(cc1)ccc1S(C)=O Chemical compound CCC(c1cc(F)ccc11)=C(C)/C1=C/c(cc1)ccc1S(C)=O AVEKESWOQKDHBQ-ODLFYWEKSA-N 0.000 description 1
- ACVGTNMVWSOJAS-UHFFFAOYSA-N CCC1(CC)OCCC2C(C=CC=C3CC)C3=NC12 Chemical compound CCC1(CC)OCCC2C(C=CC=C3CC)C3=NC12 ACVGTNMVWSOJAS-UHFFFAOYSA-N 0.000 description 1
- COIRSVPTDJIIKY-UHFFFAOYSA-N CCOC(Cc(c1c2)c(C)[n](C(c(cc3)ccc3Cl)=O)c1ccc2OC)=O Chemical compound CCOC(Cc(c1c2)c(C)[n](C(c(cc3)ccc3Cl)=O)c1ccc2OC)=O COIRSVPTDJIIKY-UHFFFAOYSA-N 0.000 description 1
- WXQQYIHRTGHQNG-UHFFFAOYSA-N CCc(cccc1)c1Nc(c(Cl)ccc1)c1Cl Chemical compound CCc(cccc1)c1Nc(c(Cl)ccc1)c1Cl WXQQYIHRTGHQNG-UHFFFAOYSA-N 0.000 description 1
- SFWPKKAWFSDSPB-UHFFFAOYSA-N CCc1c(C)[n](C(c(cc2)ccc2Cl)=O)c(cc2)c1cc2OC Chemical compound CCc1c(C)[n](C(c(cc2)ccc2Cl)=O)c(cc2)c1cc2OC SFWPKKAWFSDSPB-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Natural products COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000607872 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 21 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KIDXYAWWICJAFK-UHFFFAOYSA-N O.[Na].OC Chemical compound O.[Na].OC KIDXYAWWICJAFK-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100039918 Ubiquitin carboxyl-terminal hydrolase 21 Human genes 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940089466 nalfon Drugs 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100266979A CN101550119B (zh) | 2009-05-11 | 2009-05-11 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
US13/320,101 US8703975B2 (en) | 2009-05-11 | 2009-12-24 | Aryl (ethanoic) propanoic acid ascorbyl ester, preparation method thereof and medicament containing the same |
PCT/CN2009/075994 WO2010130139A1 (zh) | 2009-05-11 | 2009-12-24 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
JP2012510092A JP2012526151A (ja) | 2009-05-11 | 2009-12-24 | アリルプロピオン酸系ビタミンcステアレート、その調製方法及びそれらを含有する薬物 |
EP09844550A EP2431361A4 (en) | 2009-05-11 | 2009-12-24 | ESTER ACETATE / ARYLIC PROPIONATE OF ASCORBIC ACID, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100266979A CN101550119B (zh) | 2009-05-11 | 2009-05-11 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101550119A CN101550119A (zh) | 2009-10-07 |
CN101550119B true CN101550119B (zh) | 2012-05-30 |
Family
ID=41154640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100266979A Expired - Fee Related CN101550119B (zh) | 2009-05-11 | 2009-05-11 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8703975B2 (zh) |
EP (1) | EP2431361A4 (zh) |
JP (1) | JP2012526151A (zh) |
CN (1) | CN101550119B (zh) |
WO (1) | WO2010130139A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101550119B (zh) | 2009-05-11 | 2012-05-30 | 无锡宏瑞生物医药科技有限公司 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
CN102772402A (zh) * | 2012-08-14 | 2012-11-14 | 中山大学 | 维生素c-布洛芬酯在制备脑靶向制剂中的应用及其制备方法 |
CN102827893A (zh) * | 2012-09-07 | 2012-12-19 | 江南大学 | 一种芳基乙(丙)酸l-抗坏血酸酯的酯交换法合成工艺 |
CN105125536B (zh) * | 2015-07-29 | 2018-05-04 | 无锡宏瑞生物医药科技有限公司 | 治疗细菌、真菌、病毒或寄生虫引起的皮肤病的组合物 |
AR102172A1 (es) | 2015-10-05 | 2017-02-08 | Química Luar S R L | Una composición farmacéutica bactericida y virucida |
RU2629367C1 (ru) | 2016-11-02 | 2017-08-29 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Нестероидное противовоспалительное средство на основе напроксена, обладающее низкой гастротоксичностью |
CN107445872B (zh) * | 2017-09-08 | 2020-04-28 | 四川护理职业学院 | 一种具有潜在脑靶向性的化合物及其制备方法与应用 |
IT202000031025A1 (it) * | 2020-12-16 | 2022-06-16 | Univ Degli Studi Di Ferrara | Enzymatic process for the preparation of esters of poorly water-soluble carboxylic acids. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008017346A2 (de) * | 2006-08-11 | 2008-02-14 | Merck Patent Gmbh | Verwendung von ascorbinsäurederivaten zur funktionalisierung von matrices |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1175500B1 (de) * | 1999-05-05 | 2004-08-04 | Cognis Deutschland GmbH & Co. KG | Verfahren zur selektiven veresterung von polyolen |
WO2004032845A2 (en) * | 2002-10-07 | 2004-04-22 | Encore Pharmaceuticals, Inc. | R-nsaid esters and their use |
US6924129B2 (en) * | 2002-10-23 | 2005-08-02 | Polytechnic University | Enzyme-catalyzed esterification of pendant carboxylic acid groups |
CN1629303A (zh) * | 2004-08-24 | 2005-06-22 | 魏嘉士 | L-抗坏血酸不饱和脂肪酸酯酶催合成方法 |
CN101080436B (zh) * | 2004-12-16 | 2010-09-22 | 陶氏康宁公司 | 抗坏血酸和2-酮酸糖的酯衍生物 |
JP2009035509A (ja) * | 2007-08-01 | 2009-02-19 | Green Products Laboratory Ltd | アスコルビン酸エステル及びその合成方法 |
CN101220119A (zh) * | 2008-01-23 | 2008-07-16 | 中国科学院化学研究所 | 一种超支化共聚物及其制备方法 |
CN101550119B (zh) | 2009-05-11 | 2012-05-30 | 无锡宏瑞生物医药科技有限公司 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
-
2009
- 2009-05-11 CN CN2009100266979A patent/CN101550119B/zh not_active Expired - Fee Related
- 2009-12-24 WO PCT/CN2009/075994 patent/WO2010130139A1/zh active Application Filing
- 2009-12-24 US US13/320,101 patent/US8703975B2/en not_active Expired - Fee Related
- 2009-12-24 EP EP09844550A patent/EP2431361A4/en not_active Withdrawn
- 2009-12-24 JP JP2012510092A patent/JP2012526151A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008017346A2 (de) * | 2006-08-11 | 2008-02-14 | Merck Patent Gmbh | Verwendung von ascorbinsäurederivaten zur funktionalisierung von matrices |
Non-Patent Citations (3)
Title |
---|
ALESSANDRO DALPIAZ,et al..Transporter-Mediated Effects of Diclofenamic Acid and Its Ascorbyl Pro-drug in the In Vivo Neurotropic Activity of Ascorbyl Nipecotic Acid Conjugate.《JOURNAL OF PHARMACEUTICAL SCIENCES》.2004,第93卷(第1期),78-84. * |
Stefano Manfredini,et al..Design, Synthesis and Activity of Ascorbic Acid Prodrugs of Nipecotic,Kynurenic and Diclophenamic Acids,Liable to Increase Neurotropic Activity.《J. Med. Chem.》.2002,第45卷(第3期),559-562. * |
StefanoManfredini et al..Design |
Also Published As
Publication number | Publication date |
---|---|
US20120115897A1 (en) | 2012-05-10 |
EP2431361A4 (en) | 2012-11-07 |
EP2431361A1 (en) | 2012-03-21 |
JP2012526151A (ja) | 2012-10-25 |
US8703975B2 (en) | 2014-04-22 |
WO2010130139A1 (zh) | 2010-11-18 |
CN101550119A (zh) | 2009-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101550119B (zh) | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 | |
TWI232865B (en) | Crystalline clindamycin free base | |
JP2009500345A (ja) | 4−フェニル酪酸ナトリウムを含む液体剤形の調製方法 | |
JP2008542316A (ja) | o−アセチルサリチル酸の塩基性アミノ酸との塩およびグリシンの安定な活性化合物複合体 | |
JPS638354A (ja) | ジアセチルライン塩及び関節炎の治療におけるそれらの使用 | |
US4952565A (en) | Inclusion complex of ibuproxam with beta-cyclodextrin, a process for preparing the same and a pharmaceutical preparation containing the same | |
WO2009133431A1 (en) | Oral liquid compositions of rhein or diacerein | |
WO1994028031A9 (en) | New nimesulide salt cyclodextrin inclusion complexes | |
CN111333692A (zh) | 一种白桦脂酸衍生物及其制备方法和应用 | |
RU2522455C2 (ru) | Способ синтеза производного эфира и глицирретиновой кислоты и соединение сложного эфира дезоксиглицирретиновой кислоты | |
CN101524546B (zh) | 聚乙二醇和姜黄素衍生物缀合的缀合物 | |
CN102453060B (zh) | 水杨酸乙酯苷类化合物、合成方法及其用途 | |
UA75656C2 (en) | Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture | |
CN101665449A (zh) | 他米巴罗汀的水溶性前药及其制备方法与应用 | |
CN107619428B (zh) | 鸟氨酸与门冬氨酸二肽化合物的酰化衍生物及其应用 | |
JPS60501561A (ja) | アゾ−ビス−サリチル酸およびその塩、該酸および該塩の薬学的処方および使用、並びに該酸の製造 | |
CN114349665B (zh) | 二甲双胍焦谷氨酸晶体及其制备方法与应用 | |
US5419915A (en) | Medicament with an analgesic, antipyretic and/or antiphlogistic action and use of 2-ethoxybenzoic acid | |
CA2055682A1 (en) | Complexes containing s(+) phenyl alkane acids and -hydroxyalkane acids | |
CN102079715A (zh) | 一种二元酯酸的赖氨酸盐化合物,其制备方法和药物应用 | |
CN113999274A (zh) | 一种替米考星-糖精共晶体及其制备方法 | |
CN102381986A (zh) | 一种右旋布洛芬氨丁三醇盐及其口服溶液的制备方法 | |
WO2005087701A1 (fr) | Nouveaux 2-($g(a)-n-pentanonyl)benzoates, preparation et utilisation associees | |
PT85291B (pt) | Processo para a preparacao de um novo aspartado de guanidinio | |
WO2008063024A1 (en) | Inclusion complex of sibutramine and beta-cyclodextrin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Wuxi Hongrui Bio-Pharma-Tech Co.,Ltd. Assignor: Jiangnan University|Tang Ning Contract record no.: 2010320001132 Denomination of invention: New heterocyclic aminomethyl compounds, process for preparing them and pharmaceutical compositions containing them License type: Exclusive License Open date: 20091007 Record date: 20100920 |
|
ASS | Succession or assignment of patent right |
Owner name: WUXI HONGRUI BIOMEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: JIANGNAN UNIVERSITY Effective date: 20101129 Free format text: FORMER OWNER: TANG NING |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 214028 NO.94, XINHUA ROAD, NEW DISTRICT, WUXI CITY, JIANGSU PROVINCE, NATIONAL UNIVERSITY SCIENCE PARK, JIANGNAN UNIVERSITY, WUXI CITY, JIANGSU PROVINCE TO: 214122 NO.100, JINXI ROAD, WUXI CITY, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20101129 Address after: 214122 Jiangsu Province, Wuxi City Jinxi Road No. 100 Applicant after: Wuxi Hongrui Bio-Pharma-Tech Co.,Ltd. Address before: 214028 Wuxi University of national science and technology, Jiangnan University, Jiangsu, Jiangsu, Wuxi New District, Xinhua Road, 94 Applicant before: Jiangnan University Co-applicant before: Tang Ning |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: WUXI HONGRUI BIOMEDICAL TECHNOLOGY CO., LTD. Effective date: 20120418 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120418 Address after: School of medicine Jiangnan University No. 1800 214122 Jiangsu city of Wuxi Province Li Lake Avenue Patentee after: Tang Luhong Address before: 214122 Jiangsu Province, Wuxi City Jinxi Road No. 100 Patentee before: Wuxi Hongrui Bio-Pharma-Tech Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 |